Vertex Pharmaceuticals (NASDAQ: VRTX) has agreed to acquire Crinetics Pharmaceuticals (NASDAQ: CRNX) for $85.00 per share in cash, representing a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE